» Articles » PMID: 36792201

Evaluating Risk Factors for Developing Allergic Reactions During Plasma Exchange Using Fresh-frozen Plasma: A Single-center Retrospective Study

Overview
Journal Intern Med
Specialty General Medicine
Date 2023 Feb 15
PMID 36792201
Authors
Affiliations
Soon will be listed here.
Abstract

Objective Allergic reactions are a severe complication of plasma exchange (PEx). Few reports have analyzed allergic reactions during PEx using fresh-frozen plasma (FFP) as a replacement solution. We therefore clarified the relationship between risk and exacerbation factors that lead to the onset of PEx-related allergic reactions, particularly PEx, using FFP, and examined whether or not allergic reactions were predictable. Methods This retrospective study included 88 consecutive patients who underwent PEx with FFP as a replacement solution at Kitasato University Hospital. The patients were grouped according to the presence of allergic reactions and compared. Data were analyzed using the χ test, Mann-Whitney U test, and a binomial logistic analysis. Statistical analyses were performed using EZR software program, version 1.54, with p<0.05 considered statistically significant. Results There were 44 allergic reaction cases. The average time to the onset of an allergic reactions was 63.5 (45-93) minutes. The allergic reaction-onset group had significantly higher average albumin (Alb) levels than did the non-allergic reaction-onset group. The binomial logistic analysis identified Alb levels as independent risk factors for allergic reactions. The receiver operating characteristic analysis identified an Alb level ≥3.4 g/dL as a risk factor for allergic reactions (area under the curve: 0.731; 95% confidence interval: 0.622-0.84). Conclusion Allergic reaction onset occurred approximately one hour after PEx initiation in the critical period. A serum Alb level ≥3.4 g/dL was identified as a risk factor for predicting allergic reactions. Patients with Alb levels ≥3.4 g/dL at the first PEx should be monitored for allergic reaction symptoms.

References
1.
Higuchi N, Yamazaki H, Kikuchi H, Gejyo F . Anaphylactoid reaction induced by a protease inhibitor, nafamostat mesilate, following nine administrations in a hemodialysis patient. Nephron. 2000; 86(3):400-1. DOI: 10.1159/000045822. View

2.
Chen D, Flythe J . Dialysis-associated allergic reactions during continuous renal replacement therapy and hemodialysis: A case report. Hemodial Int. 2019; 24(1):E5-E9. PMC: 7214049. DOI: 10.1111/hdi.12801. View

3.
Castells M . Diagnosis and management of anaphylaxis in precision medicine. J Allergy Clin Immunol. 2017; 140(2):321-333. DOI: 10.1016/j.jaci.2017.06.012. View

4.
Kim H, Lee K, Oh J, Jung C, Choi D, Kim Y . Cardiac arrest caused by nafamostat mesilate. Kidney Res Clin Pract. 2016; 35(3):187-9. PMC: 5025458. DOI: 10.1016/j.krcp.2015.10.003. View

5.
Savage W, Tobian A, Savage J, Wood R, Schroeder J, Ness P . Scratching the surface of allergic transfusion reactions. Transfusion. 2012; 53(6):1361-71. PMC: 3711222. DOI: 10.1111/j.1537-2995.2012.03892.x. View